期刊
GENES & DEVELOPMENT
卷 31, 期 23-24, 页码 2337-2342出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.307116.117
关键词
PTEN; SMAD4; TGFBR2; BMPR2; prostate cancer; bone metastasis
资金
- Clayton and Modesta Williams Cancer Research Fund
- MD Anderson Cancer Center [P30CA016672]
- Department of Defense Prostate Cancer Research Program (PCRP) [W81XWH-14-1-0576]
- Indiana Clinical and Translational Sciences Institute (CTSI) - National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award [KL2TR001106, UL1TR001108]
- [R01 CA084628]
- [P01CA117969]
SMAD4 constrains progression of Pten-null prostate cancer and serves as a common downstream node of transforming growth factor beta (TGF beta) and bone morphogenetic protein (BMP) pathways. Here, we dissected the roles of TGF beta receptor II (TGFBR2) and BMP receptor II (BMPR2) using a Pten-null prostate cancer model. These studies demonstrated that the molecular actions of TGFBR2 result in both SMAD4-dependent constraint of proliferation and SMAD4-independent activation of apoptosis. In contrast, BMPR2 deletion extended survival relative to Pten deletion alone, establishing itspromoting role in BMP6-driven prostate cancer progression. These analyses reveal the complexity ofTGF beta-BMPsignaling and illuminate potential therapeutic targets for prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据